



The *European Journal of Cancer* would like to announce:

**A Special Issue entitled:
“Preclinical Models in Cancer Drug Discovery and
Development”
Issue 40.6 (2004)**

Titles include:

- Update on NCI *in vitro* drug screen utilities
- *In vitro* modelling of human tumour behaviour in drug discovery programmes
- Clonogenic assays with established human tumour xenografts: correlation of *in vitro* to *in vivo* activity as a basis for anti-cancer drug discovery
- The hollow fibre model in cancer drug screening: the NCI experience
- “Of mice and men”: values and liabilities of the athymic nude mouse model in anticancer drug development
- Integrating pharmacology and *in vivo* models in preclinical and clinical drug development
- *In vivo* models for endocrine-dependent breast carcinomas: special considerations of clinical relevance
- Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages
- Spontaneous and genetically engineered animal models: use in preclinical cancer drug development
- Modelling approaches for angiogenesis
- A potential role for imaging technology in anticancer efficacy evaluations
- The Cancer Research UK experience of preclinical toxicology studies to support early clinical trials with novel cancer therapies
- Multi-species toxicology approaches for oncology drugs: the US perspective

Special Issue Guest Editors: Edward A. Sausville and David R. Newell